(UroToday.com) Androgen deprivation therapy (ADT) has been a cornerstone in the treatment of advanced prostate cancer for decades. While initially indicated for patients with metastatic disease alone, its use has expanded. Thus, while ADT has proven survival benefits, there is an increasing need to understand the costs associated with its use in the management of biochemical recurrence (BCR), metastatic hormone sensitive prostate cancer (mHSPC) and castration resistant prostate cancer (CRPC).